Key statistics
As of last trade Insmed Inc (INSM:NSQ) traded at 145.95, -31.40% below its 52-week high of 212.75, set on Dec 02, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 149.49 |
|---|---|
| High | 149.83 |
| Low | 145.52 |
| Bid | 145.85 |
| Offer | 146.22 |
| Previous close | 148.55 |
| Average volume | 2.26m |
|---|---|
| Shares outstanding | 213.27m |
| Free float | 211.37m |
| P/E (TTM) | -- |
| Market cap | 31.68bn USD |
| EPS (TTM) | -6.18 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 16:01 GMT.
More ▼
- Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
- Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
- Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
- Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
- Insmed Provides Clinical and Business Update
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
- European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
More ▼
